 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- || BD111 / BDgene
New P2 trial, Stroma: A Phase ?a Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis (clinicaltrials.gov) - Jun 25, 2024
P2, N=40, Not yet recruiting, Sponsor: Shanghai BDgene Co., Ltd.
- || BD111 / BDgene
New P1 trial, Stroma: A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis (clinicaltrials.gov) - Jun 24, 2024
P1, N=16, Recruiting, Sponsor: Shanghai BDgene Co., Ltd.
- || BD111 / BDgene
Trial completion, Phase classification, Trial primary completion date: Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis (clinicaltrials.gov) - Aug 24, 2022
P=N/A, N=3, Completed, Sponsor: Shanghai BDgene Co., Ltd.
Active, not recruiting --> Completed | Phase classification: P1/2 --> PN/A | Trial primary completion date: Nov 2021 --> Jul 2022
- || BD311 / BDgene
New P1 trial, Gene therapy: VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases (clinicaltrials.gov) - Oct 28, 2021
P1, N=18, Recruiting, Sponsor: Shanghai BDgene Co., Ltd.
- BD111 / BDgene
Enrollment closed, Trial initiation date: Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis (clinicaltrials.gov) - May 26, 2021
P1/2, N=6, Active, not recruiting, Sponsor: Shanghai BDgene Co., Ltd.
Active, not recruiting --> Completed | Phase classification: P1/2 --> PN/A | Trial primary completion date: Nov 2021 --> Jul 2022 Recruiting --> Active, not recruiting | Initiation date: Mar 2021 --> Nov 2020
- BD111 / BDgene
Trial initiation date: Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis (clinicaltrials.gov) - Mar 12, 2021
P1/2, N=6, Recruiting, Sponsor: Shanghai BDgene Co., Ltd.
Recruiting --> Active, not recruiting | Initiation date: Mar 2021 --> Nov 2020 Initiation date: Dec 2020 --> Mar 2021
- BD111 / BDgene
Phase classification: Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis (clinicaltrials.gov) - Oct 17, 2020
P1/2, N=6, Recruiting, Sponsor: Shanghai BDgene Co., Ltd.
Initiation date: Dec 2020 --> Mar 2021 Phase classification: P=N/A --> P1/2
- | BD111 / BDgene
New P1/2 trial, New trial: Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis (clinicaltrials.gov) - Sep 22, 2020
P=N/A, N=6, Recruiting, Sponsor: Shanghai BDgene Co., Ltd.